Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is proud to announce the launch of its D
The Nobel Prize in Physiology or Medicine awarded
This year, the Hamburg based life sciences company
Alembic Pharmaceuticals Ltd., t
Since it’s an ingredient in so many foods, you h
Dear Readers, Welcome to the latest issue of Micr
New Delhi, Nov 12 (PTI) Drug firm Lupin on Thursday stated that in alliance with Concord Biotech, it has obtained acceptance from the US health regulator to market generic immunosuppressant Tacrolimus capsules used in the Western industry. In cooperation with Concord Biotech, the business has obtained approval from the United States Food and Drug Administration (USFDA) to advertise Tacrolimus capsules USP, at the advantages of 0.5 mg, 1 mg, and 5 milligrams, Lupin said in a filing to the BSE.
The product is a standard version of Astellas Pharma US, Inc”s Prograf capsules at exactly the very same strengths, it added.
According to IQVIA MAT September 2020 data, Tacrolimus capsules USP (0.5 mg, 1 mg, and 5 mg) had an yearly sales of about USD 303 million at the united states, Lupin explained.
The capsules are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, heart or kidney transplant, in conjunction with other immunosuppressants, it included.
Shares of Lupin Ltd on Thursday dropped 1.76 percent to Rs 897.70 per scrip on t
he BSE. PTI AKT HRS
